|
|
|
|
|
|
|
|
Abstract
Background: Neoadjuvant
chemotherapy has shown a modest benefit in muscle-invasive bladder
cancer patients; however, the subset of patients
most likely to benefit has not been identified.
BRCA1 plays a central role in DNA repair pathways and low BRCA1
expression
has been associated with sensitivity to cisplatin
and longer survival in lung and ovarian cancer patients.
Patients and methods: We
assessed BRCA1 messenger RNA expression levels in paraffin-embedded
pre-treatment tumor samples obtained by transurethral
resection from 57 patients with locally advanced
bladder cancer subsequently treated with neoadjuvant cisplatin-based
chemotherapy.
BRCA1 levels were divided into terciles and
correlated with pathological response and survival....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.